Cargando…
Importance of eculizumab treatment in recurrence of atypical hemolytic uremic syndrome during the SARS-CoV-2 pandemic
Autores principales: | Tatar, Erhan, Erdi, Zuleyha Can, Ozgur, Oyku, Tasdemir, Anıl, Tatar, Bengu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128974/ https://www.ncbi.nlm.nih.gov/pubmed/34003430 http://dx.doi.org/10.1007/s11255-021-02890-y |
Ejemplares similares
-
Efficacy of Eculizumab in Coexisting Complement C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome
por: Busutti, Marco, et al.
Publicado: (2020) -
The Importance of Eculizumab in the Treatment of Atypical Hemolytic Uremic Syndrome
por: Santos, Mariana S, et al.
Publicado: (2022) -
Atypical Hemolytic and Uremic Syndrome Triggered by Infection With SARS-CoV2
por: Kaufeld, Jessica, et al.
Publicado: (2021) -
An adult case of atypical hemolytic uremic syndrome presented with posterior reversible encephalopathy syndrome: Successful response to late-onset eculizumab treatment
por: Medeni, Serife Solmaz, et al.
Publicado: (2018) -
Eculizumab, SARS-CoV-2 and atypical hemolytic uremic syndrome
por: Trimarchi, Hernán, et al.
Publicado: (2020)